Danazol treatment of chronic cystic mastopathy: a clinical and hormonal evaluation.
Danazol effectively relieved chronic cystic mastopathy symptoms in women, with significant side effects including amenorrhea, irregular bleeding, and weight gain, linked to its ovulation-inhibiting hormonal effects.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (7)
- Danazol alters mitochondria metabolism of fibrocystic breast Mcf10A cells 2017
- Cyclical mastopathy: A critical review of therapy 1988
- Treatment of recurrent cyclical mastodynia in patients with fibrocystic breast disease 1984
- Danazol treatment of severely symptomatic fibrocystic breast disease and long‐term follow‐up—the Hjørring project 1984
- The influence of danazol on pituitary function and on the ovarian follicular hormone secretion in premenopausal women 1984
- Peripheral androgen levels in danazol-treated premenopausal women 1983
- CONTROLLED TRIAL OF THE ANTIGONADOTROPIN DANAZOL IN PAINFUL NODULAR BENIGN BREAST DISEASE 1982
Source provenance
- openalex
- last seen: 2026-05-10T10:54:23.571943+00:00